2022
Clinical and Ethical Framework for Liver Retransplantation Using Living Donor Grafts: A Western Perspective
Batra RK, Mulligan DC. Clinical and Ethical Framework for Liver Retransplantation Using Living Donor Grafts: A Western Perspective. Liver Transplantation 2022, 28: 760-762. PMID: 34931433, DOI: 10.1002/lt.26395.Peer-Reviewed Original Research
2021
Inactive status is an independent predictor of liver transplant waitlist mortality and is associated with a transplant centers median meld at transplant
Merola J, Gan G, Stewart D, Noreen S, Mulligan D, Batra R, Haakinson D, Deng Y, Kulkarni S. Inactive status is an independent predictor of liver transplant waitlist mortality and is associated with a transplant centers median meld at transplant. PLOS ONE 2021, 16: e0260000. PMID: 34793524, PMCID: PMC8601542, DOI: 10.1371/journal.pone.0260000.Peer-Reviewed Original ResearchConceptsDonor service areasWaitlist mortalityTransplant centersMedian MELDHigh mortalityStatus changesLiver transplant waitlist mortalityDeceased donor transplantsInactive statusTransplant probabilityInactive patientsMELD scoreDonor transplantsHazard ratioIndependent predictorsTransplant ratesCare coordinationMortalityPatientsTransplantLevel cohortsTertileSignificant differencesCohortMELDDeveloping simultaneous liver‐kidney transplant medical eligibility criteria while providing a safety net: A 2‐year review of the OPTN's allocation policy
Wilk AR, Booker SE, Stewart DE, Wiseman A, Gauntt K, Mulligan D, Formica RN. Developing simultaneous liver‐kidney transplant medical eligibility criteria while providing a safety net: A 2‐year review of the OPTN's allocation policy. American Journal Of Transplantation 2021, 21: 3593-3607. PMID: 34254434, DOI: 10.1111/ajt.16761.Peer-Reviewed Original ResearchConceptsMedical Eligibility CriteriaEligibility criteriaLiver transplantPatient/graft survivalWaitlist mortality rateDeceased donor kidneysLiver recipientsSLK candidatesSLK transplantsGraft survivalRenal impairmentPosttransplant outcomesDonor kidneysTransplant ratesTransplant volumeMortality rateTransplantKidneySignificant differencesRecipientsSubsequent increaseLiver dataCriteriaImpairmentSLK
2020
Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation
Tefera J, Revzin M, Chapiro J, Savic L, Mulligan D, Batra R, Taddei T, Jain D, Zhang X. Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation. Journal Of Clinical Pathology 2020, 74: 31-35. PMID: 32430483, PMCID: PMC7674234, DOI: 10.1136/jclinpath-2020-206574.Peer-Reviewed Original ResearchConceptsAdvanced Barcelona Clinic Liver Cancer stageBarcelona Clinic Liver Cancer stageScirrhous HCCMultiple rounded nodulesNon-peripheral washoutLiver Cancer stageRadiological featuresClinical featuresRadiological correlationCarcinoma variantsCancer stageHCC casesHepatocellular carcinomaLiver cancerFibrotic liverConventional HCCHCCLower ratesHigh rateRounded nodulesProgressionDistinct patternsCarcinomaSpecific variantsLesions
2018
Successful treatment of primary donor‐derived human herpesvirus‐8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient
Fu W, Merola J, Malinis M, Lacy J, Barbieri A, Liapakis AH, Mulligan DC, Yoo PS. Successful treatment of primary donor‐derived human herpesvirus‐8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient. Transplant Infectious Disease 2018, 20: e12966. PMID: 30014622, DOI: 10.1111/tid.12966.Peer-Reviewed Case Reports and Technical NotesConceptsHuman herpesvirus 8 infectionHepatic Kaposi sarcomaKaposi's sarcomaTransplant recipientsAdult liver transplant recipientsRegression of KSSplit liver transplantAcute cellular rejectionLiver transplant recipientsSuccessful therapeutic strategiesAllograft functionCellular rejectionLiver transplantSeropositive donorsSuccessful treatmentLiposomal doxorubicinTherapeutic strategiesRecipientsSarcomaInfectionTreatmentImmunosuppressionPatientsMalignancyTransplant
2017
Liver retransplantation: Recurrent primary sclerosing cholangitis may provide better outcomes
Choe J, Mulligan DC. Liver retransplantation: Recurrent primary sclerosing cholangitis may provide better outcomes. Liver Transplantation 2017, 23: 730-732. PMID: 28425147, DOI: 10.1002/lt.24777.Peer-Reviewed Original Research
2016
Resolving Misconceptions About Liver Allocation and Redistricting Methodology
Gentry SE, Hirose R, Mulligan D. Resolving Misconceptions About Liver Allocation and Redistricting Methodology. JAMA Surgery 2016, 151: 991-992. PMID: 27333440, DOI: 10.1001/jamasurg.2016.1315.Peer-Reviewed Original Research
2014
Magnetic resonance elastography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation
Gallegos-Orozco JF, Silva AC, Batheja MJ, Chang YH, Hansen KL, Lam-Himlin D, De Petris G, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan DC, Silva AM, Rakela J, Vargas HE. Magnetic resonance elastography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. Abdominal Radiology 2014, 40: 795-802. PMID: 25445158, DOI: 10.1007/s00261-014-0310-y.Peer-Reviewed Original ResearchConceptsLive liver donationLiver biopsyLiver donationMagnetic resonance elastographyHepatic steatosisOptimal cutoffExact testPotential live liver donorsAbnormal liver biopsyAbnormal liver histologyLive liver donorsDegree of steatosisDonor evaluation processLiver biopsy resultsROC curveFisher's exact testLiver shear stiffnessAbility of MREResonance elastographyLiver histologyBiopsy resultsLiver donorsLiver fibrosisSteatosisBiopsy
2012
Living donor safety during the performance of hepatectomy
Mulligan DC. Living donor safety during the performance of hepatectomy. Liver Transplantation 2012, 18: 1134-1135. PMID: 22821707, DOI: 10.1002/lt.23514.Peer-Reviewed Original Research
2002
Amelioration of hepatic ischemia/reperfusion injury using indolepropionic acid
Lefler SR, St. Peter SD, Rodriguez-Davalos MI, Perumean JC, Spence NA, Moss AA, Mulligan DC. Amelioration of hepatic ischemia/reperfusion injury using indolepropionic acid. Transplantation Proceedings 2002, 34: 3065-3066. PMID: 12493376, DOI: 10.1016/s0041-1345(02)03616-3.Peer-Reviewed Original Research
1995
Use of anti-hepatitis C virus seropositive organs in liver transplantation.
Mulligan DC, Goldstein RM, Crippin JS, Abouljoud MS, Levy MF, Husberg BS, Gonwa TA, Foster BR, Tillery GW, Klintmalm GB. Use of anti-hepatitis C virus seropositive organs in liver transplantation. Transplantation Proceedings 1995, 27: 1204-5. PMID: 7878850.Peer-Reviewed Original ResearchA Comparison Of Treatment With Transjugular Intrahepatic Portosystemic Shunt Or Distal Splenorenal Shunt In The Management Of Variceal Bleeding Prior To Liver Transplantation
Abouljoud M, Levy M, Rees C, Diamond N, Lee S, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. A Comparison Of Treatment With Transjugular Intrahepatic Portosystemic Shunt Or Distal Splenorenal Shunt In The Management Of Variceal Bleeding Prior To Liver Transplantation. Transplantation 1995, 59: 226-229. PMID: 7839445, DOI: 10.1097/00007890-199501270-00013.Peer-Reviewed Original ResearchConceptsTransjugular intrahepatic portosystemic shuntDistal splenorenal shuntIntrahepatic portosystemic shuntDSRS groupVariceal bleedingLiver transplantationSurgical shuntsSplenorenal shuntLiver diseasePortosystemic shuntTIPS groupRole of TIPSPrevious transjugular intrahepatic portosystemic shuntEnd-stage liver diseaseChild-Pugh C patientsIntraoperative hemodynamic measurementsSubsequent transplant procedureAdvanced liver diseaseLiver transplant candidatesLiver transplant recipientsRecurrent variceal bleedingGroup of patientsFirst-line managementBlood flow measurementsComparison of treatments